MedTrace Logo

Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease

NCT00659529 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-05-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether sildenafil can decrease inflammation in CF lung disease.

Conditions

Interventions

DRUG

sildenafil

Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.

Sponsors & Collaborators

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • National Jewish Health

    lead OTHER

Principal Investigators

  • Jennifer L Taylor-Cousar, MD · National Jewish Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2012-08-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00659529 on ClinicalTrials.gov